Thus, the changes we identified in alternative splicing of these genes are appealing potential diagnostic markers for tumor initiation in several cancers, and FBLN2, AP2B1 and TCF20 are also good prognostic markers for patient survival in breast, lung, and kidney cancers, respectively (Figure 4). The gene discussed is TCF20; the disease is kidney cancer.